Trial Profile
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 02 Sep 2013 Planned end date (30 Aug 2013) added as reported by University Hospital Medical Information Network - Japan.
- 05 Sep 2011 New trial record